Urovant Sciences Ltd. (UROV): Price and Financial Metrics
UROV Price/Volume Stats
| Current price | $16.24 | 52-week high | $16.26 |
| Prev. close | $16.23 | 52-week low | $7.15 |
| Day low | $16.21 | Volume | 1,739,000 |
| Day high | $16.24 | Avg. volume | 114,469 |
| 50-day MA | $16.19 | Dividend yield | N/A |
| 200-day MA | $12.24 | Market Cap | 531.75M |
UROV Stock Price Chart Interactive Chart >
Urovant Sciences Ltd. (UROV) Company Bio
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Latest UROV News From Around the Web
Below are the latest news stories about Urovant Sciences Ltd that investors may wish to consider to help them evaluate UROV as an investment opportunity.
NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Urovant Sciences Ltd. (Nasdaq - UROV), Cubic Corporation (NYSE - CUB), CoreLogic, Inc. (NYSE - CLGX)BALA CYNWYD, PA / ACCESSWIRE / February 13, 2021 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law .Brodsky & Smith, LLCBALA CYNWYD, PA / ACCESSWIRE / February 13, 2021 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. |
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 ResultsUrovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, NHLD, COHR, UROV; Shareholders Are Encouraged to Contact the FirmNEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: MDC Partners Inc. (NASDAQ: MDCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Stagwell Media LP. Stagwell and its affiliates are expected to hold approximately 79% of the common equity of the combined company after closing. If you are an MDC shareholder, click here to learn more about your rights and options. National Holdings Corporation (NASDAQ: NHLD) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to B. Riley Financial, Inc. for $3.25 per share. If you are a National Holdings shareholder,... |
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - CPAH, UROV, ANH, CGIX, CBLI, NEOSHalper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: |
SHAREHOLDER ALERT: WeissLaw LLP Reminds JWS, BRPA, and UROV Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
UROV Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 0.93% |
| 5-year | 107.14% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 4.00% |
| 2019 | 135.36% |
| 2018 | N/A |
Loading social stream, please wait...